|Bid||25.49 x 1300|
|Ask||25.54 x 1000|
|Day's range||25.10 - 25.78|
|52-week range||13.19 - 76.10|
|Beta (5Y monthly)||0.75|
|PE ratio (TTM)||N/A|
|Earnings date||06 Dec 2022 - 12 Dec 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||32.92|
The average of price targets set by Wall Street analysts indicates a potential upside of 25.7% in Phreesia (PHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
WILMINGTON, Del., September 22, 2022--Phreesia, a leader in patient intake, outreach and activation, has named Alexandra Beneville as Vice President of Life Sciences Content Strategy. Beneville officially joined Phreesia on Aug. 1, 2022, from Phosphorus, a direct-to-consumer genomic testing company, where she had served as Vice President of Marketing since December 2021.
WILMINGTON, Del., September 16, 2022--Phreesia is proud to announce that Zeeshan Butt, PhD, a Director of Clinical Content, has been selected to serve a three-year term as a member of the National Quality Forum (NQF)’s Measure Applications Partnership (MAP) 2022-2023 Clinician Workgroup.